Secondary analysis of a phase 3 trial in 80 patients with advanced melanoma given TIL: responders received more CD8+TCRαβ+ T cells (P=0.029), and their frequency in the infusion product was associated with 6-month PFS (P<0.0001).
Secondary analysisn = 80
Granhøj et al. Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma